Identifying the critical genes in that differentiate gall bladder cancer from the normal gall bladder and the related biological terms are the aim of this study.
Molecular mechanism underlying gall bladder cancer (GBC) trigger and developments still requires investigations. Potential therapeutic biomarkers can be identified through protein-protein interaction network prediction of proteome as a complementary study.
Here, a literature review of proteomics studies of Gall bladder cancer from 2010 to 2019 was handled to screen differentially expressed proteins in this cancer. A network of 27 differentially expressed proteins (DEPs) via Cytoscape 3.7.1 and its plug-ins was constructed and analyzed.
Ten proteins were introduced as hub-bottlenecks that among them four were from DEPs. The gene ontology analysis also indicated that Positive regulation of multi-organism process and regulation of response to biotic stimulus are the most disrupted biological processes of GBC considering their relationships with the DEPs.
ACTG, ALB, GGH, and DYNC1H1 and relative biological terms were introduced as drug targets and possible diagnostic biomarker.
Tan Y, Ma S-Y, Wang F-Q, Meng H-P, Mei C, Liu A, et al. Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer. Oncology reports. 2011;26(4):853-9.
Wi Y, Woo H, Won Y-J, Jang J-Y, Shin A. Trends in gallbladder cancer incidence and survival in Korea. Cancer research and treatment: official journal of Korean Cancer Association. 2018;50(4):1444.
Jaruvongvanich V, Yang JD, Peeraphatdit T, Roberts LR. The incidence rates and survival of gallbladder cancer in the USA. European Journal of Cancer Prevention. 2019;28(1):1-9.
Tuo J, Zhang M, Zheng R, Zhang S, Li G, Yang N, et al. Report of incidence and mortality of gallbladder cancer in China, 2014. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2018;40(12):894-9.
Huang H-L, Yao H-S, Wang Y, Wang W-J, Hu Z-Q, Jin K-Z. Proteomic identification of tumor biomarkers associated with primary gallbladder cancer. World Journal of Gastroenterology: WJG. 2014;20(18):5511.
Farrokhi Yekta R, Arefi Oskouie A, Rezaei Tavirani M, Mohajeri-Tehrani MR, Soroush AR. Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study. The International journal of biological markers. 2018;33(4):455-62.
Mahboubi M, Azodi MZ, Tavirani MR, Mansouri V, Ahmadi NA, Hamdieh M, et al. Protein-Protein Interaction Analysis of Common Top Genes in Obsessive-Compulsive Disorder (OCD) and Schizophrenia: Towards New Drug Approach Obsessive-Compulsive disorder (OCD) and Schizophrenia Comorbidity Gene Analysis. Iranian journal of pharmaceutical research: IJPR. 2018;17(Suppl2):173.
-Tavirani M, Zamanian-Azodi M, Rezaei-Tavirani M, Vafaee R. Interaction network prediction and analysis of Anorexia Nervosa. Iranian Journal of Child Neurology. 2019;13(3):45-54.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003;13(11):2498-504.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic acids research. 2016:gkw937.
Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013;29(5):661-3.
Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091-3.
Bhunia S, Barbhuiya MA, Gupta S, Shrivastava BR, Tiwari PK. Abstract A14: Downregulation of desmin involves gene promoter hypermethylation in gallbladder cancer. AACR; 2018.
Sahasrabuddhe NA, Barbhuiya MA, Bhunia S, Subbannayya T, Gowda H, Advani J, et al. Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics. Biochemical and biophysical research communications. 2014;446(4):863-9.
Barbhuiya MA, Subbannayya T, Leal-Rojas PA, Shahasrabudhe N, Renuse S, Patil AH, et al. Su1999 Proteomic Analysis of Gallbladder Cancer to Identify Biomarkers and Therapeutic Targets. Gastroenterology. 2015;148(4):S-571.
Truckenmueller F, Goeppert B, Pusch S, Heinze I, Kirkpatrick J, Schirmacher P, et al., editors. Mass-spectrometric analysis of deregulated proteins in gallbladder carcinoma. JOURNAL OF HEPATOLOGY; 2019: ELSEVIER SCIENCE BV PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
Tan Y, Meng H, Wu Q, Wang F, Wu H. Proteomic study of gallbladder cancer, with special reference on the expression and significance of annexin A3. Zhonghua bing li xue za zhi= Chinese journal of pathology. 2010;39(6):382-6.
Subbannayya T, Leal-Rojas P, Zhavoronkov A, Ozerov IV, Korzinkin M, Babu N, et al. PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40). Journal of cell communication and signaling. 2019;13(2):163-77.
Bhunia S, Gupta S, Shrivastava BR, Tiwari PK. Identification of S100 calcium binding protein A9 as a prognostic biomarker in gallbladder cancer. Meta Gene. 2018;18:62-7.
Rai R, Gosai S, Rao CV, Chandra V. Molecular Diagnosis of Gall Bladder Cancer. Molecular Diagnostics in Cancer Patients: Springer; 2019. p. 11-25.
Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120(22):3446-56.
Li X-W, Tuergan M, Abulizi G. Expression of MAPK1 in cervical cancer and effect of MAPK1 gene silencing on epithelial-mesenchymal transition, invasion and metastasis. Asian Pacific journal of tropical medicine. 2015;8(11):937-43.
Najar AG, Pashaei-Asl R, Omidi Y, Farajnia S, Nourazarian AR. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. Asian Pacific Journal of Cancer Prevention. 2013;14(1):495-8.
Reyes-Gibby CC, Wang J, Silvas MRT, Yu R, Yeung S-CJ, Shete S. MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients. BMC genetics. 2016;17(1):40.
Mohri D, Ijichi H, Miyabayashi K, Takahashi R, Kudo Y, Sasaki T, et al. A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. Journal of gastroenterology. 2016;51(7):711-21.
Buchegger K, Silva R, López J, Ili C, Araya JC, Leal P, et al. The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer. Pathology-Research and Practice. 2017;213(5):476-82.
Luger T, Kokoschka E, Sagaster P, Micksche M. Serum lysozyme levels in patients with solid tumors. Oncology. 1979;36(1):15-8.
Serra C, Vizoso F, Alonso L, Rodríguez JC, González LO, Fernández M, et al. Expression and prognostic significance of lysozyme in male breast cancer. Breast Cancer Research. 2002;4(6):R16.
Sai K, Onda M, Ozawa Y, Honjo T, Okuda T, Sumiyama Y. Relationship between metaplastic changes and occurrence of endocrin cells, lysozyme and lactoferrin in gallbladder carcinoma. Annals of Cancer Research and Therapy. 1998;7(1):34-8.
Sucularli C, Arslantas M. Computational prediction and analysis of deleterious cancer associated missense mutations in DYNC1H1. Molecular and cellular probes. 2017;34:21-9.
Gong L-B, Wen T, Li Z, Xin X, Che X-F, Wang J, et al. DYNC1I1 Promotes the Proliferation and Migration of Gastric Cancer by Up-Regulating IL-6 Expression. Frontiers in Oncology. 2019;9.
Guo C, Liu S, Wang J, Sun M-Z, Greenaway FT. ACTB in cancer. Clinica Chimica Acta. 2013;417:39-44.
Yang L, Yang Z, Tan X, Miao X. Expression of annexin A1 (ANXA1) and A2 (ANXA2) and its significance in benign and malignant lesions of gallbladder. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2010;32(8):595-9.
Wang C-Y, Lin C-F. Annexin A2: its molecular regulation and cellular expression in cancer development. Disease markers. 2014;2014.
Christensen MV, Høgdall CK, Jochumsen KM, Høgdall EV. Annexin A2 and cancer: A systematic review. International journal of oncology. 2018;52(1):5-18.
Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, et al. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. International journal of molecular sciences. 2017;18(2):286.
Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, et al. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. BMC cancer. 2013;13(1):47.
Sadahiro S, Suzuki T, Tanaka A, Okada K, Saito G, Miyakita H, et al. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer. Cancer chemotherapy and pharmacology. 2017;79(6):1077-85.
Dong X, Han Y, Sun Z, Xu J. Actin Gamma 1, a new skin cancer pathogenic gene, identified by the biological feature‐based classification. Journal of cellular biochemistry. 2018;119(2):1406-19.
Po ‘uha ST, Kavallaris M. Gamma-actin is involved in regulating centrosome function and mitotic progression in cancer cells. Cell Cycle. 2015;14(24):3908-19.
Iqbal MA, Siddiqui FA, Gupta V, Chattopadhyay S, Gopinath P, Kumar B, et al. Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Molecular cancer. 2013;12(1):72.